Abstract
Antibody formation is an intended physiological reaction to a “non-self” protein intentionally triggered in the case of vaccines. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to systematically assess an unwanted immune response following the administration of a biological drug. In this article, we discuss key aspects of this guideline and its concept, with a particular focus on the impact of immunogenicity on benefit/risk estimation of a therapeutic protein.
Keywords: Immunogenicity, biotechnology derived proteins, benefit/risk, risk assessment, regulatory guideline
Current Drug Safety
Title: Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals
Volume: 5 Issue: 4
Author(s): Isabel C. Buttel, Katrin Voller and Christian K. Schneider
Affiliation:
Keywords: Immunogenicity, biotechnology derived proteins, benefit/risk, risk assessment, regulatory guideline
Abstract: Antibody formation is an intended physiological reaction to a “non-self” protein intentionally triggered in the case of vaccines. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to systematically assess an unwanted immune response following the administration of a biological drug. In this article, we discuss key aspects of this guideline and its concept, with a particular focus on the impact of immunogenicity on benefit/risk estimation of a therapeutic protein.
Export Options
About this article
Cite this article as:
Buttel C. Isabel, Voller Katrin and Schneider K. Christian, Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792245993
DOI https://dx.doi.org/10.2174/157488610792245993 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naringenin Scaffold as a Template for Drug Designing
Current Traditional Medicine Glutamate and Psychosis Risk
Current Pharmaceutical Design Pivotal Pathogenic and Biomarker Role of Chlamydia Pneumoniae in Neurovascular Diseases
Current Neurovascular Research Acetylcholinesterase Inhibitors as Pretreatment Before Acute Exposure to Organophosphates: Assessment Using Methyl-Paraoxon
CNS & Neurological Disorders - Drug Targets Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway
Current Nanoscience Smart Mesoporous Silica Nanocarriers for Antitumoral Therapy
Current Topics in Medicinal Chemistry Kidney Dysfunction is Associated with a High Burden of Cerebral Small Vessel Disease in Primary Intracerebral Hemorrhage
Current Neurovascular Research Cannabinoid Receptor Activation and the Endocannabinoid System in the Gastrointestinal Tract
Current Neuropharmacology New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets Depression Under the Perspective of Oxytocin
Central Nervous System Agents in Medicinal Chemistry Ion Selective Electrodes for Potentiometric Determination of Tizanidine in Its Pharmaceutical Dosage Form
Current Pharmaceutical Analysis Human Whey Promotes Sessile Bacterial Growth, Whereas Alternative Sources of Infant Nutrition Promote Planktonic Growth
Current Nutrition & Food Science Ketamine: New Indications for an Old Drug
Current Drug Targets Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Current Pharmaceutical Design Radiometal Complexes in Molecular Imaging and Therapy
Current Medicinal Chemistry Chlorophytum borivilianum: A White Gold for Biopharmaceuticals and Neutraceuticals
Current Pharmaceutical Biotechnology Disconnection of Language and Memory in Semantic Dementia: A Comparative and Theoretical Analysis
Current Alzheimer Research Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Increased Paternal Age and Child Health and Development
Current Pediatric Reviews